Borda Mederos Luis A, Chiroque Benites Luis I, Pinto Elera Jesús O, Manzaneda Pineda Ana J
Servicio de Coloproctología del Hospital Nacional Guillermo Almenara Irigoyen, EsSalud.
Rev Gastroenterol Peru. 2011 Oct-Dec;31(4):345-50.
Treatment of complex anal fistula is a surgical challenge because the risk of sphincter injury with the possibility of developing fecal incontinence. There are many techniques for the treatment of anal fistulas such as fistulotomy, fistulectomy, seton, endorectal advancement flap and fibrin glue, with different rates of recurrence and fecal incontinence. The biologic plug Surgisis® AFP it's being used since 2006 and produces the closure of the fistula in approximately 12 weeks, without surgery, by replacement of the fistulous tract by cells of the patient, apparently having advantages over other techniques.We retrospectively reviewed the results of 46 patients with complex anorectal fistula treated with the biological plug over a period of 4 years. Of these, 34 were men (73.9%) and 12 women, the mean age was 47.2 years. According the type of fistula, 41 were recurrent fistulas (89.1%) and 5 high transsphincteric fistulas (10.8%). Patients underwent surgery on average 2.2 times previously. The anal fistula plug was successful in 73.9% of cases with a median follow-up 29.8 months. Use of anal fistula plug Surgisis® AFP is a new alternative with acceptable results in terms of recurrence comparable to other techniques, but with no incontinence.
复杂性肛瘘的治疗是一项外科挑战,因为存在括约肌损伤及发生大便失禁的风险。治疗肛瘘有多种技术,如肛瘘切开术、瘘管切除术、挂线疗法、直肠推进皮瓣术和纤维蛋白胶,其复发率和大便失禁率各不相同。生物补片Surgisis® AFP自2006年起开始使用,无需手术,通过患者自身细胞替代瘘管,约12周内实现瘘管闭合,显然比其他技术更具优势。我们回顾性分析了46例复杂性肛瘘患者在4年期间使用生物补片治疗的结果。其中,男性34例(73.9%),女性12例,平均年龄47.2岁。根据肛瘘类型,复发性肛瘘41例(89.1%),高位经括约肌肛瘘5例(10.8%)。患者此前平均接受过2.2次手术。肛瘘补片治疗成功率为73.9%,中位随访时间29.8个月。使用肛瘘补片Surgisis® AFP是一种新的治疗选择,在复发率方面与其他技术相当且效果可接受,但不会导致大便失禁。